Indication: Jaundice

A phase 2B, mulit-center, single dose, blinded, randomized, placebo-controlled, dose escalation, safety and efficacy trial of Stannsoporfin in neonates with Hyperbilirubinemia.

Sub-indication: Jaundice

Drug Study - IND

Principal Investigator: Dan Stewart, M.D.
Norton Children's Neonatology, affiliated with the UofL School of Medicine

Sponsor: InfaCare Pharmaceutical Corporation

Search our entire site.